美国血液技术 HAE 深 沪
已收盘 05-15 16:00:00 美东时间
56.29
-0.830
-1.45%
华盛通- 最 高58.18
- 今 开57.27
- 成交量 91.19万股
- 最 低 56.26
- 昨 收 57.12
- 总市值 261.59万
- 52周最高 87.32
- 市盈率 静 27.39
- 换手率 1962.30%
- 52周最低 47.315
- 委 比 -57.89%
- 总股本 4.65万
- 历史最高 142.11
- 量 比 0.86
- 振 幅 3.36%
- 历史最低 25.98
- 每 手 1
- 风险率 10.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
JP Morgan Maintains Neutral on Haemonetics, Lowers Price Target to $62
JP Morgan analyst Allen Gong maintains Haemonetics (NYSE:HAE) with a Neutral and lowers the price target from $74 to $62.
05-09 02:32
财报速睇 | 美国血液技术 2026财年Q1营收3.46亿美元，同比增长4.8%；归母净利润亏损0.20亿美元，由盈转亏
华盛资讯5月7日讯，美国血液技术公布2026财年Q1业绩，公司Q1营收3.46亿美元，同比增长4.8%，归母净利润亏损0.20亿美元，由盈转亏。
05-07 18:46
Haemonetics Sees FY2027 Adj EPS $5.26-$5.31 vs $5.29 Est; Sees Sales $1.410B-$1.427B vs $1.394B Est
FISCAL 2027 GUIDANCEThe Company issued its fiscal 2027 GAAP total revenueand organic revenue growth guidance as follows: Total CompanyReported Revenue4 - 7%53rd week
05-07 18:16
Haemonetics Q4 Adj. EPS $1.29 Beats $1.27 Estimate, Sales $346.351M Beat $336.862M Estimate
Haemonetics (NYSE:HAE) reported quarterly earnings of $1.29 per share which beat the analyst consensus estimate of $1.27 by 1.57 percent. This is a 4.03 percent increase over earnings of $1.24 per share from the same
05-07 18:12
Haemonetics to Present at Bank of America 2026 Healthcare Conference
BOSTON, May 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Bank of Ameri...
05-05 18:00
Haemonetics study shows VASCADE MVP XL outperforms VASCADE MVP in large-bore venous closure
Haemonetics study shows VASCADE MVP XL outperforms VASCADE MVP in large-bore venous closure Haemonetics reported publication of a new single-center study comparing VASCADE MVP XL with VASCADE MVP for large-bore venous access closure in electrophysiology procedures. Study results were already publish
04-24 18:20
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Mizuho Maintains Outperform on Haemonetics, Lowers Price Target to $70
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $80 to $70.
04-14 01:25
